Clinical benefits of PD-1/PD-L1 inhibitors in patients with metastatic colorectal cancer: a systematic review and meta-analysis

被引：0
|
作者：
Xiao Zhang
Zhengyang Yang
Yongbo An
Yishan Liu
Qi Wei
Fengming Xu
Hongwei Yao
Zhongtao Zhang
机构：
[1] Capital Medical University,Department of General Surgery, Beijing Friendship Hospital
来源：
World Journal of Surgical Oncology | / 20卷
关键词：
Immune checkpoint inhibitors; Colorectal neoplasms; Meta-analysis; Clinical efficacy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Assessment of the Clinical Trials Safety Profile of PD-1/PD-L1 Inhibitors Among Patients With Cancer: An Updated Systematic Review and Meta-Analysis
    Tian, Yuan
    Huang, Alan
    Yang, Yue
    Dang, Qi
    Wen, Qing
    Wang, Linlin
    Sun, Yuping
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
  • [22] Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
    Xiaodi Guo
    Wendong Li
    Jiexuan Hu
    Emily C. Zhu
    Qiang Su
    [J]. European Journal of Clinical Pharmacology, 2020, 76 : 1345 - 1354
  • [23] Hepatotoxicity in patients with solid tumors treated with PD-1/PD-L1 inhibitors alone, PD-1/PD-L1 inhibitors plus chemotherapy, or chemotherapy alone: systematic review and meta-analysis
    Guo, Xiaodi
    Li, Wendong
    Hu, Jiexuan
    Zhu, Emily C.
    Su, Qiang
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2020, 76 (10) : 1345 - 1354
  • [24] Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis
    Han, Songfei
    Guo, Cuishan
    Song, Zixuan
    Ouyang, Ling
    Wang, Yizi
    [J]. FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [25] The predictive value of PD-L1 expression in patients with advanced hepatocellular carcinoma treated with PD-1/PD-L1 inhibitors: A systematic review and meta-analysis
    Yang, Yao
    Chen, Dongbo
    Zhao, Bigeng
    Ren, Liying
    Huang, Rui
    Feng, Bo
    Chen, Hongsong
    [J]. CANCER MEDICINE, 2023, 12 (08): : 9282 - 9292
  • [26] EFFICACY AND SAFETY OF PD-1/PD-L1 INHIBITORS USED IN THE TREATMENT OF PATIENTS WITH ADVANCED AND METASTATIC MELANOMA - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Oguzhan, G.
    Caliskan, Z.
    Kockaya, G.
    Kurnaz, M.
    Calli, C.
    Erturk, S. M.
    [J]. VALUE IN HEALTH, 2020, 23 : S50 - S50
  • [27] EFFICACY AND SAFETY OF PD-1/PD-L1 INHIBITORS USED IN THE TREATMENT OF PATIENTS WITH ADVANCED AND METASTATIC MELANOMA - A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
    Verma, J.
    Verma, D.
    Maria, A.
    [J]. VALUE IN HEALTH, 2020, 23 : S50 - S50
  • [28] Review of PD-1/PD-L1 Inhibitors in Metastatic dMMR/MSI-H Colorectal Cancer
    Oliveira, Andre F.
    Bretes, Luis
    Furtado, Irene
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [29] Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis
    Huang, Shibo
    Huang, Yanping
    Li, Chunyan
    Liang, Yiwen
    Huang, Miaoyan
    Luo, Raoshan
    Liang, Weiming
    [J]. FRONTIERS IN IMMUNOLOGY, 2024, 14
  • [30] Cardiac adverse events of PD-1 and PD-L1 inhibitors in cancer protocol for a systematic review and network meta-analysis: A protocol for systematic review
    Han, Deting
    Dong, Jianyong
    Li, Honglin
    Ma, Tao
    Yu, Wenjun
    Song, Lucheng
    [J]. MEDICINE, 2020, 99 (05) : E18701
12345